Cargando…

Investigating the impact of open label design on patient‐reported outcome results in prostate cancer randomized controlled trials

BACKGROUND: While open‐label randomized controlled trials (RCT) are common in oncology, some concerns have been expressed with regard to Patient‐Reported Outcomes (PRO)‐based claims stemming from these studies. We aimed to investigate the impact of open‐label design in the context of prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mouillet, Guillaume, Efficace, Fabio, Thiery‐Vuillemin, Antoine, Charton, Emilie, Van Hemelrijck, Mieke, Sparano, Francesco, Anota, Amélie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571808/ https://www.ncbi.nlm.nih.gov/pubmed/32846465 http://dx.doi.org/10.1002/cam4.3335

Ejemplares similares

Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient‐reported outcomes in randomized controlled trials to support clinical decision‐making
por: Van Hemelrijck, Mieke, et al.
Publicado: (2020)

Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review
por: Van Hemelrijck, Mieke, et al.
Publicado: (2019)

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol
por: Mouillet, Guillaume, et al.
Publicado: (2019)

Evaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocol
por: Deliu, Nina, et al.
Publicado: (2018)

Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
por: Thiery‐Vuillemin, Antoine, et al.
Publicado: (2021)

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial
por: Mouillet, Guillaume, et al.
Publicado: (2018)

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study
por: CAUBET, MATTHIEU, et al.
Publicado: (2015)

Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
por: Häggström, Christel, et al.
Publicado: (2016)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Heterogeneity in risk of prostate cancer: A Swedish population‐based cohort study of competing risks and Type 2 diabetes mellitus
por: Häggström, Christel, et al.
Publicado: (2018)

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
por: Cheng, Larry C., et al.
Publicado: (2018)

Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories
por: Arthur, Rhonda, et al.
Publicado: (2016)

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
por: Charton, Emilie, et al.
Publicado: (2019)

Is there a role for IGF‐1 in the development of second primary cancers?
por: Shanmugalingam, Thurkaa, et al.
Publicado: (2016)

Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases
por: George, Gincy, et al.
Publicado: (2020)

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review
por: Ousmen, Ahmad, et al.
Publicado: (2018)

Serum leptin, C‐reactive protein, and cancer mortality in the NHANES III
por: Wulaningsih, Wahyu, et al.
Publicado: (2015)

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
por: Beckmann, Kerri, et al.
Publicado: (2021)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

Expectant management in genitourinary malignancies (prostate, bladder, kidney)
por: Van Hemelrijck, Mieke, et al.
Publicado: (2021)

The Profile of Emotional Competence (PEC): A French short version for cancer patients
por: Baudry, Anne-Sophie, et al.
Publicado: (2020)

Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis
por: Alpert, Evgenia, et al.
Publicado: (2021)

A mediation analysis to explain socio‐economic differences in bladder cancer survival
por: Russell, Beth, et al.
Publicado: (2020)

Family history of breast cancer and its association with disease severity and mortality
por: Melvin, Jennifer C., et al.
Publicado: (2016)

Incidence of Second Malignancies for Prostate Cancer
por: Van Hemelrijck, Mieke, et al.
Publicado: (2014)

Prostate Cancer, Prostate Cancer Death, and Death from Other Causes, Among Men with Metabolic Aberrations
por: Häggström, Christel, et al.
Publicado: (2014)

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
por: Nerich, Virginie, et al.
Publicado: (2014)

Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory
por: Van Hemelrijck, Mieke, et al.
Publicado: (2016)

Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)
por: Perez‐Cornago, Aurora, et al.
Publicado: (2017)

Intake of individual fatty acids and risk of prostate cancer in the European prospective investigation into cancer and nutrition
por: Perez‐Cornago, Aurora, et al.
Publicado: (2019)

Research engagement among black men with prostate cancer
por: Toms, Charlotte, et al.
Publicado: (2016)

Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials
por: Giesinger, Johannes M., et al.
Publicado: (2021)

P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE?
por: Perthus, Alya, et al.
Publicado: (2023)

Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
por: Smith, Matthew R, et al.
Publicado: (2023)

Revisiting the roles of cAMP signalling in the progression of prostate cancer
por: Parsons, Emma C., et al.
Publicado: (2023)

Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis
por: Taylor, Amy E., et al.
Publicado: (2016)

Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
por: Efficace, Fabio, et al.
Publicado: (2022)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
por: Kudchadkar, Ragini, et al.
Publicado: (2015)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lq0cqbpb0hm8s6ll4je1cm8b8i